

Director Appointment – Jacqueline Fernley

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce the appointment of Jacqueline Fernley as an Independent Non-Executive Director to the Microba Board. The appointment is effective immediately.

Microba’s Chair Pasquale Rombola and Deputy-Chair Professor Ian Frazer, said “We are delighted to welcome Jacqui to the Board. Jacqui has over 25 years’ experience in leading teams and developing products within the financial services sector. She is an experienced investor and has a high degree of financial literacy, capital raising experience and a strong understanding of financial markets and investors. Jacqui’s experience and skills will be a positive addition to the current Microba Board of Directors”

Jacqueline currently serves as the Chief Investment Officer (CIO) of Mason Stevens where she leads the asset management division of the firm. Prior to joining Mason Stevens, Jacqueline had previously roles as Head of Equities at J B Were Limited, Head of Research at Wilson HTM and Australian Equity Portfolio Manager at Colonial First State Global Asset Management. Jacqueline has a Bachelor of Commerce/Law degree, is a holder of the Chartered Financial Analyst (CFA) designation and is a graduate of the Australian Institute of Company Directors (GAICD).

Jacqueline is also intimately involved in mentoring and supporting women in the financial services industry and ESG, regularly presenting to investment committees, boards, and management on the topics. She was recently appointed to the diversity committee of NSW CFA Society.

This announcement has been authorised for release by the Board.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.